Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01020799 · ClinicalTrials.gov registry record · Phase 2
AZD7268 Safety and Tolerability Study
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 247
- Enrollment target
NCT01020799: Completed Phase 2 study, sponsored by AstraZeneca.
NCT01020799 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 247 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01020799, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 247 participants
- Enrollment target
Study Summary
The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.
Primary Outcome
MADRS total score, sum of 10 item scores (each on a 0 (best value) to 6 (worst value)scale), assesses the severity of depressive symptoms on a continuous scale from 0 (the best) to 60 (the worst). Change from baseline was calculated as Week 4 value minus baseline value. \[observed cases, Mixed Model Repeated Measurement (MMRM), Full Analysis Set (FAS)\]
Interventions
- DRUG Escitalopram
- DRUG Placebo capsules
- DRUG Placebo tablets
- DRUG AZD7268
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
What the finished NCT01020799 record still lists
NCT01020799 is an interventional study that assigns participants to a tested intervention. The registered 247 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% higher).
The record links to 0 conditions, and to 4 interventions - of which Escitalopram is the first listed.
NCT01020799 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01020799 about?
NCT01020799 is a clinical study titled "AZD7268 Safety and Tolerability Study". The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.
What is the current status of trial NCT01020799?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 247 participants. The study started on 2009-11. Estimated completion is 2010-04.
What interventions are being tested in trial NCT01020799?
The interventions under investigation include: Escitalopram (DRUG), Placebo capsules (DRUG), Placebo tablets (DRUG), AZD7268 (DRUG).
Who is sponsoring clinical trial NCT01020799?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01020799's enrollment target sits among peer trials
247 234th of 2000 higher than 1,767 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04269902 · 247 participants · Phase 3
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- NCT04989803 · 247 participants · Phase 1
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
- NCT05521399 · 247 participants
Heart Transplantation - Renewal
- NCT05556824 · 247 participants · Phase 2
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia